Promising role of polymeric nanoparticles in the treatment of rheumatoid arthritis.
Arthritis
Inflammation
Nanoparticles
Polymers
Journal
Inflammopharmacology
ISSN: 1568-5608
Titre abrégé: Inflammopharmacology
Pays: Switzerland
ID NLM: 9112626
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
30
01
2022
accepted:
11
04
2022
pubmed:
8
5
2022
medline:
22
7
2022
entrez:
7
5
2022
Statut:
ppublish
Résumé
Rheumatoid arthritis (RA) is a chronic inflammatory illness caused by an autoimmune disorder of synovial membrane resulting in synovial membrane dysfunction. The available treatment particularly focuses on inhibiting macrophage proliferation and reducing the generation of pro-inflammatory cytokines. However, therapeutic success of current treatment options at targeted site is limited; therefore, development of promising therapeutic strategy is the need of time that may provide better targeted delivery of drug with added safety. In development of precision medicine to manage RA, nanotechnology is a viable option to be considered. Recent research using nanoparticles for the treatment of RA, particularly polymeric nanoparticles, has been discussed in this article. Using polymeric nanoparticles as a therapeutic method has shown considerable promise of enhancing treatment success over standard medications used in routine. It is exclusively evident that the viability of using nanoparticles is mainly owed due to their biocompatibility, chemical stability, controlled drug release, and selective drug delivery to inflamed tissues in RA model animals. The current analysis focuses on the critical design characteristics of RA-targeted nanotechnology-based strategies in quest of better therapeutic strategies for RA, and to identify leading polymer as the most effective medications in RA therapy.
Identifiants
pubmed: 35524837
doi: 10.1007/s10787-022-00997-x
pii: 10.1007/s10787-022-00997-x
doi:
Substances chimiques
Polymers
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1207-1218Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Aggarwal BB, Harikumar KB (2009) Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 41(1):40–59
pubmed: 18662800
doi: 10.1016/j.biocel.2008.06.010
Alamanos Y, Voulgari PV, Drosos AA (2006) Incidence and prevalence of rheumatoid arthritis, based on the 1987 American college of rheumatology criteria: a systematic review. Paper presented at the Seminars in arthritis and rheumatism.
Albuquerque J, Moura CC, Sarmento B, Reis S (2015) Solid lipid nanoparticles: a potential multifunctional approach towards rheumatoid arthritis theranostics. Molecules 20(6):11103–11118
pubmed: 26087258
pmcid: 6272405
doi: 10.3390/molecules200611103
Aletaha D, Alasti F, Smolen JS (2015) Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials. Arthritis Res Ther 17(1):1–10
doi: 10.1186/s13075-015-0736-9
Anquetil F, Clavel C, Offer G, Serre G, Sebbag M (2015) IgM and IgA rheumatoid factors purified from rheumatoid arthritis sera boost the Fc receptor–and complement-dependent effector functions of the disease-specific anti–citrullinated protein autoantibodies. J Immunol 194(8):3664–3674
pubmed: 25769920
doi: 10.4049/jimmunol.1402334
Arias JL, López-Viota M, López-Viota J, Delgado ÁV (2009) Development of iron/ethylcellulose (core/shell) nanoparticles loaded with diclofenac sodium for arthritis treatment. Int J Pharm 382(1–2):270–276
pubmed: 19712736
doi: 10.1016/j.ijpharm.2009.08.019
Arora R, Kuhad A, Kaur I, Chopra K (2015) Curcumin loaded solid lipid nanoparticles ameliorate adjuvant-induced arthritis in rats. Eur J Pain 19(7):940–952
pubmed: 25400173
doi: 10.1002/ejp.620
Bajpayee AG, Grodzinsky AJ (2017) Cartilage-targeting drug delivery: can electrostatic interactions help? Nat Rev Rheumatol 13(3):183–193
pubmed: 28202920
doi: 10.1038/nrrheum.2016.210
Bengtsson K, Jacobsson LT, Rydberg B, Kvist G, Torstenson T, Dehlin M, Forsblad-d’Elia H (2016) Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study. BMC Musculoskelet Disord 17(1):1–10
doi: 10.1186/s12891-016-1354-7
Berenbaum F, Pham T, Claudepierre P, De Chalus T, Joubert J-M, Saadoun C, Fautrel B (2018) Early non-response to certolizumab pegol in rheumatoid arthritis predicts treatment failure at one year. Data from a randomised Phase III clinical trial. Jt Bone Spine 85(1):59–64
doi: 10.1016/j.jbspin.2017.01.011
Böhler C, Radner H, Smolen JS, Aletaha D (2013) Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis. Ann Rheum Dis 72(2):241–244
pubmed: 23087181
doi: 10.1136/annrheumdis-2012-202297
Both S, de Cokelaere S, Wang R, Vos N, Li G, Lin Y, Karperien M (2016) Injectable enzymatically cross linkable hydrogels: a minimally invasive cell free approach to regenerate damaged articular cartilage. Osteoarthr Cartil 24:S161
doi: 10.1016/j.joca.2016.01.317
Branco JC, Barcelos A, de Araújo FP, Sequeira G, Cunha I, Patto JV, Nero P (2016) Utilization of subcutaneous methotrexate in rheumatoid arthritis patients after failure or intolerance to oral methotrexate: a multicenter cohort study. Adv Ther 33(1):46–57
pubmed: 26724937
pmcid: 4735239
doi: 10.1007/s12325-015-0276-3
Cheng R, Meng F, Deng C, Klok H-A, Zhong Z (2013) Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. Biomaterials 34(14):3647–3657
pubmed: 23415642
doi: 10.1016/j.biomaterials.2013.01.084
Cheng CJ, Tietjen GT, Saucier-Sawyer JK, Saltzman WM (2015) A holistic approach to targeting disease with polymeric nanoparticles. Nat Rev Drug Discov 14(4):239–247
pubmed: 25598505
pmcid: 4451203
doi: 10.1038/nrd4503
Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, Johns N (2014) The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73(7):1316–1322
pubmed: 24550173
doi: 10.1136/annrheumdis-2013-204627
Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V (2012) PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 161(2):505–522
pubmed: 22353619
doi: 10.1016/j.jconrel.2012.01.043
de Hair MJ, Zijlstra IA, Boumans MJ, van de Sande MG, Maas M, Gerlag DM, Tak PP (2012) Hunting for the pathogenesis of rheumatoid arthritis: core-needle biopsy of inguinal lymph nodes as a new research tool. Ann Rheum Dis 71(11):1911–1912
pubmed: 22689316
doi: 10.1136/annrheumdis-2012-201540
Dewangan AK, Varkey S, Mazumder S. (2015) Synthesis of curcumin loaded CMCAB nanoparticles for treatment of rheumatoid arthritis. Paper presented at the International conference on chemical, environmental and biological sciences (CEBS)
Diamanti AP, Laganà B, Cox MC, Pilozzi E, Amodeo R, Bove M, Sorgi ML (2017) TCD4 pos lymphocytosis in rheumatoid and psoriatic arthritis patients following TNFα blocking agents. J Transl Med 15(1):1–6
doi: 10.1186/s12967-016-1111-6
Dolati S, Sadreddini S, Rostamzadeh D, Ahmadi M, Jadidi-Niaragh F, Yousefi M (2016) Utilization of nanoparticle technology in rheumatoid arthritis treatment. Biomed Pharmacother 80:30–41
pubmed: 27133037
doi: 10.1016/j.biopha.2016.03.004
Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, Szarka E (2012) Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Investig 122(5):1791–1802
pubmed: 22505457
pmcid: 3336988
doi: 10.1172/JCI60975
Hawkes JE, Chan TC, Krueger JG (2017) Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol 140(3):645–653
pubmed: 28887948
pmcid: 5600287
doi: 10.1016/j.jaci.2017.07.004
Heo R, Park J-S, Jang HJ, Kim S-H, Shin JM, Suh YD, Park JH (2014) Hyaluronan nanoparticles bearing γ-secretase inhibitor: in vivo therapeutic effects on rheumatoid arthritis. J Control Release 192:295–300
pubmed: 25109660
doi: 10.1016/j.jconrel.2014.07.057
Higaki M, Ishihara T, Izumo N, Takatsu M, Mizushima Y (2005) Treatment of experimental arthritis with poly (D, L-lactic/glycolic acid) nanoparticles encapsulating betamethasone sodium phosphate. Ann Rheum Dis 64(8):1132–1136
pubmed: 15695536
pmcid: 1755606
doi: 10.1136/ard.2004.030759
Honda K, Littman DR (2012) The microbiome in infectious disease and inflammation. Annu Rev Immunol 30:759–795
pubmed: 22224764
pmcid: 4426968
doi: 10.1146/annurev-immunol-020711-074937
Horisawa E, Hirota T, Kawazoe S, Yamada J, Yamamoto H, Takeuchi H, Kawashima Y (2002a) Prolonged anti-inflammatory action of DL-lactide/glycolide copolymer nanospheres containing betamethasone sodium phosphate for an intra-articular delivery system in antigen-induced arthritic rabbit. Pharm Res 19(4):403–410
pubmed: 12033371
doi: 10.1023/A:1015123024113
Horisawa E, Kubota K, Tuboi I, Sato K, Yamamoto H, Takeuchi H, Kawashima Y (2002b) Size-dependency of DL-lactide/glycolide copolymer particulates for intra-articular delivery system on phagocytosis in rat synovium. Pharm Res 19(2):132–139
pubmed: 11883639
doi: 10.1023/A:1014260513728
Hu X, Chakravarty SD, Ivashkiv LB (2008) Regulation of interferon and toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol Rev 226(1):41–56
pubmed: 19161415
pmcid: 2630590
doi: 10.1111/j.1600-065X.2008.00707.x
Humby F, Kelly S, Hands R, Rocher V, DiCicco M, Ng N, Caporali R (2015) Use of ultrasound-guided small joint biopsy to evaluate the histopathologic response to rheumatoid arthritis therapy: recommendations for application to clinical trials. Arthritis Rheumatol 67(10):2601–2610
pubmed: 26097225
doi: 10.1002/art.39235
Hwang J, Rodgers K, Oliver JC, Schluep T (2008) α-Methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy. Int J Nanomed 3(3):359
Ishihara T, Kubota T, Choi T, Higaki M (2009) Treatment of experimental arthritis with stealth-type polymeric nanoparticles encapsulating betamethasone phosphate. J Pharmacol Exp Ther 329(2):412–417
pubmed: 19244548
doi: 10.1124/jpet.108.150276
Ishihara T, Takahashi M, Higaki M, Mizushima Y, Mizushima T (2010) Preparation and characterization of a nanoparticulate formulation composed of PEG-PLA and PLA as anti-inflammatory agents. Int J Pharm 385(1–2):170–175
pubmed: 19837147
doi: 10.1016/j.ijpharm.2009.10.025
Ivorra JAR, Ivorra J, Monte-Boquet E, Canal C, Oyagüez I, Gómez-Barrera M (2016) Cost analysis of biologic drugs in rheumatoid arthritis first line treatment after methotrexate failure according to patients’ body weight. Reumatol Clín (English Edition) 12(3):123–129
doi: 10.1016/j.reumae.2015.07.006
James EA, Rieck M, Pieper J, Gebe JA, Yue BB, Tatum M, Malmström V (2014) Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy. Arthritis Rheumatol 66(7):1712–1722
pubmed: 24665079
pmcid: 4248674
doi: 10.1002/art.38637
Kim WU, Lee WK, Ryoo JW, Kim SH, Kim J, Youn J, Park SH (2002) Suppression of collagen-induced arthritis by single administration of poly (lactic-co-glycolic acid) nanoparticles entrapping type II collagen: a novel treatment strategy for induction of oral tolerance. Arthritis Rheum: Off J Am Coll Rheumatol 46(4):1109–1120
doi: 10.1002/art.10198
Kitas GD, Gabriel SE (2011) Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 70(1):8–14
pubmed: 21109513
doi: 10.1136/ard.2010.142133
Klarenbeek P, De Hair M, Doorenspleet M, Van Schaik B, Esveldt R, Van De Sande M, Van Kampen A (2012) Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease. Ann Rheum Dis 71(6):1088–1093
pubmed: 22294635
doi: 10.1136/annrheumdis-2011-200612
Lai P, Daear W, Löbenberg R, Prenner EJ (2014) Overview of the preparation of organic polymeric nanoparticles for drug delivery based on gelatine, chitosan, poly (d, l-lactide-co-glycolic acid) and polyalkylcyanoacrylate. Colloids Surf, B 118:154–163
doi: 10.1016/j.colsurfb.2014.03.017
Lee W-K, Park J-Y, Jung S, Yang CW, Kim W-U, Kim H-Y, Park J-S (2005) Preparation and characterization of biodegradable nanoparticles entrapping immunodominant peptide conjugated with PEG for oral tolerance induction. J Control Release 105(1–2):77–88
pubmed: 15919128
doi: 10.1016/j.jconrel.2005.03.009
Manders SH, Kievit W, Adang E, Brus HL, Moens HJB, Hartkamp A, Vonkeman HE (2015) Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. Arthritis Res Ther 17(1):1–12
doi: 10.1186/s13075-015-0630-5
McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205–2219
pubmed: 22150039
doi: 10.1056/NEJMra1004965
Medina SH, El-Sayed ME (2009) Dendrimers as carriers for delivery of chemotherapeutic agents. Chem Rev 109(7):3141–3157
pubmed: 19534493
doi: 10.1021/cr900174j
Nogueira E, Gomes AC, Preto A, Cavaco-Paulo A (2016) Folate-targeted nanoparticles for rheumatoid arthritis therapy. Nanomed Nanotechnol Biol Med 12(4):1113–1126
doi: 10.1016/j.nano.2015.12.365
Park J-S, Kim S-H, Kim K, Jin C-H, Choi KY, Jang J, Yun UJ (2015) Inhibition of notch signalling ameliorates experimental inflammatory arthritis. Ann Rheum Dis 74(1):267–274
pubmed: 24255545
doi: 10.1136/annrheumdis-2013-203467
Periyathambi P, Sastry TP, Anandasadagopan SK, Manickavasagam K (2017) Macrophages mediated diagnosis of rheumatoid arthritis using fibrin based magnetic nanoparticles as MRI contrast agents. Biochim Biophys Acta Gen Sub 1861:2992–3001
doi: 10.1016/j.bbagen.2016.09.018
Pham CT (2011) Nanotherapeutic approaches for the treatment of rheumatoid arthritis. Wiley Interdiscip Rev Nanomed Nanobiotechnol 3(6):607–619
pubmed: 21837725
pmcid: 3800699
doi: 10.1002/wnan.157
Pridgen EM, Alexis F, Farokhzad OC (2015) Polymeric nanoparticle drug delivery technologies for oral delivery applications. Expert Opin Drug Deliv 12(9):1459–1473
pubmed: 25813361
pmcid: 4835173
doi: 10.1517/17425247.2015.1018175
Rodrigues FS, Campos A, Martins J, Ambrosio AF, Campos EJ (2020) Emerging trends in nanomedicine for improving ocular drug delivery: light-responsive nanoparticles, mesoporous silica nanoparticles, and contact lenses. ACS Biomater Sci Eng 6(12):6587–6597
pubmed: 33320633
doi: 10.1021/acsbiomaterials.0c01347
Rombouts Y, Ewing E, van de Stadt LA, Selman MH, Trouw LA, Deelder AM, Toes RE (2015) Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Ann Rheum Dis 74(1):234–241
pubmed: 24106048
doi: 10.1136/annrheumdis-2013-203565
Rombouts Y, Willemze A, van Beers JJ, Shi J, Kerkman PF, van Toorn L, Pruijn GJ (2016) Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. Ann Rheum Dis 75(3):578–585
pubmed: 25587188
doi: 10.1136/annrheumdis-2014-206598
Roy K, Kanwar RK, Kanwar JR (2015) Molecular targets in arthritis and recent trends in nanotherapy. Int J Nanomed 10:5407
Runnels HA, Weber GL, Min J, Kudlacz EM, Zobel JF, Donovan CB, Salafia MA (2010) PF-03475952: a potent and neutralizing fully human anti-CD44 antibody for therapeutic applications in inflammatory diseases. Adv Ther 27(3):168–180
pubmed: 20429046
doi: 10.1007/s12325-010-0010-0
Scheinman RI, Trivedi R, Vermillion S, Kompella UB (2011) Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model. Nanomedicine 6(10):1669–1682
pubmed: 22087799
doi: 10.2217/nnm.11.90
Scher JU, Ubeda C, Artacho A, Attur M, Isaac S, Reddy SM, Patel T (2015) Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol 67(1):128–139
pubmed: 25319745
pmcid: 4280348
doi: 10.1002/art.38892
Seo B-B, Kwon Y, Kim J, Hong KH, Kim S-E, Song H-R, Song S-C (2022) Injectable polymeric nanoparticle hydrogel system for long-term anti-inflammatory effect to treat osteoarthritis. Bioactive Mater 7:14–25
doi: 10.1016/j.bioactmat.2021.05.028
Shi J, van Veelen PA, Mahler M, Janssen GM, Drijfhout JW, Huizinga TW, Trouw LA (2014) Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun Rev 13(3):225–230
pubmed: 24176675
doi: 10.1016/j.autrev.2013.10.008
Smolen JS, Aletaha D (2015) Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol 11(5):276–289
pubmed: 25687177
doi: 10.1038/nrrheum.2015.8
Sokka T, Kautiainen H, Pincus T, Verstappen SM, Aggarwal A, Alten R, Belmonte M (2010) Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther 12(2):1–10
doi: 10.1186/ar2951
Sokolove J, Johnson DS, Lahey LJ, Wagner CA, Cheng D, Thiele GM, Caplan L (2014) Rheumatoid factor as a potentiator of anti–citrullinated protein antibody–mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol 66(4):813–821
pubmed: 24757134
pmcid: 3994896
doi: 10.1002/art.38307
Sridhar V, Gaud R, Bajaj A, Wairkar S (2018) Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson’s disease. Nanomed Nanotechnol Biol Med 14(8):2609–2618
doi: 10.1016/j.nano.2018.08.004
Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Haraoui B (2016) Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis 75(1):16–22
pubmed: 25990290
doi: 10.1136/annrheumdis-2015-207526
Szeto MCH, Yalçın MD, Khan A, Piotrowicz A (2016) Successful use of tocilizumab in a patient with coexisting rheumatoid arthritis and ulcerative colitis. Case Rep Immunol 2016(4):7562123
Takamura A, Hirata S, Nagasawa H, Kameda H, Seto Y, Atsumi T, Harigai M (2013) A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc committee for safety of biological DMARDs of the Japan college of rheumatology. Mod Rheumatol 23(2):297–303
pubmed: 22572888
doi: 10.3109/s10165-012-0658-1
Thomas TP, Goonewardena SN, Majoros IJ, Kotlyar A, Cao Z, Leroueil PR, Baker JR Jr (2011) Folate-targeted nanoparticles show efficacy in the treatment of inflammatory arthritis. Arthritis Rheum 63(9):2671–2680
pubmed: 21618461
pmcid: 3168725
doi: 10.1002/art.30459
Tosh J, Archer R, Davis S, Stevenson M, Stevens JW (2013) Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs: a NICE single technology appraisal. Pharmacoeconomics 31(8):653–661
pubmed: 23576019
doi: 10.1007/s40273-013-0052-7
Wallis WJ, Simkin PA (1983) Antirheumatic drug concentrations in human synovial fluid and synovial tissue observations on extravascular pharmacokinetics. Clin Pharmacokinet 8(6):496–522
pubmed: 6360465
doi: 10.2165/00003088-198308060-00002
Wang Q, Sun X (2017) Recent advances in nanomedicines for the treatment of rheumatoid arthritis. Biomater Sci 5(8):1407–1420
pubmed: 28631779
doi: 10.1039/C7BM00254H
Wang D, Miller SC, Liu X-M, Anderson B, Wang XS, Goldring SR (2007) Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis. Arthritis Res Ther 9(1):1–9
doi: 10.1186/ar2106
Wang Y, Wei X, Zhang C, Zhang F, Liang W (2010) Nanoparticle delivery strategies to target doxorubicin to tumor cells and reduce side effects. Ther Deliv 1(2):273–287
pubmed: 22816133
doi: 10.4155/tde.10.24
Wardwell PR, Forstner MB, Bader RA (2015) Investigation of the cytokine response to NF-κB decoy oligonucleotide coated polysaccharide based nanoparticles in rheumatoid arthritis in vitro models. Arthritis Res Ther 17(1):1–11
doi: 10.1186/s13075-015-0824-x
Wiens D, Smolik I, Meng X, Anaparti V, El-Gabalawy HS, O’Neil LJ (2022) Functional disability to evaluate the risk of arthritis in first-degree relatives of patients with rheumatoid arthritis. J Rheumatol 49(3):244–250
pubmed: 34725176
doi: 10.3899/jrheum.210614
Yarwood A, Viatte S, Okada Y, Plenge R, Yamamoto K, BRAGGSS, R, Klareskog L (2016) Loci associated with N-glycosylation of human IgG are not associated with rheumatoid arthritis: a Mendelian randomisation study. Ann Rheum Dis 75(1):317–320
pubmed: 26386125
doi: 10.1136/annrheumdis-2014-207210
Ye J, Wang Q, Zhou X, Zhang N (2008) Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. Int J Pharm 352(1–2):273–279
pubmed: 18054182
doi: 10.1016/j.ijpharm.2007.10.014
Zhang J-M, An J (2007) Cytokines, inflammation and pain. Int Anesthesiol Clin 45(2):27
pubmed: 17426506
pmcid: 2785020
doi: 10.1097/AIA.0b013e318034194e
Zhang P, Li Y, Tang W, Zhao J, Jing L, McHugh KJ (2022) Theranostic nanoparticles with disease-specific administration strategies. Nano Today 42:101335
doi: 10.1016/j.nantod.2021.101335
Zhao X, Okeke NL, Sharpe O, Batliwalla FM, Lee AT, Ho PP, Robinson WH (2008) Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res Ther 10(4):1–13
doi: 10.1186/ar2478
Zheng Z, Sun Y, Liu Z, Zhang M, Li C, Cai H (2015) The effect of curcumin and its nanoformulation on adjuvant-induced arthritis in rats. Drug Des Dev Ther 9:4931
Zhou F (2009) Molecular mechanisms of IFN-γ to up-regulate MHC class I antigen processing and presentation. Int Rev Immunol 28(3–4):239–260
pubmed: 19811323
doi: 10.1080/08830180902978120
Zhou H-F, Chan HW, Wickline SA, Lanza GM, Pham CT (2009) αvβ3–targeted nanotherapy suppresses inflammatory arthritis in mice. FASEB J 23(9):2978–2985
pubmed: 19376816
pmcid: 2735365
doi: 10.1096/fj.09-129874
Zhou H-F, Hu G, Wickline SA, Lanza GM, Pham CT (2010) Synergistic effect of antiangiogenic nanotherapy combined with methotrexate in the treatment of experimental inflammatory arthritis. Nanomedicine 5(7):1065–1074
pubmed: 20874021
doi: 10.2217/nnm.10.78
Zhou H-F, Yan H, Senpan A, Wickline SA, Pan D, Lanza GM, Pham CT (2012) Suppression of inflammation in a mouse model of rheumatoid arthritis using targeted lipase-labile fumagillin prodrug nanoparticles. Biomaterials 33(33):8632–8640
pubmed: 22922023
pmcid: 3583210
doi: 10.1016/j.biomaterials.2012.08.005